FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)															
1. Name and Address of Reporting Person * NEIL GARRY ARTHUR				2. Issuer Name and Ticker or Trading Symbol Avalo Therapeutics, Inc. [AVTX]							mbol	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner					
(Last) (First) (Middle) C/O AVALO THERAPEUTICS, INC., 540 GAITHER ROAD, SUITE 400				3. Date of Earliest Transaction (Month/Day/Year) 12/10/2021							y/Year)	X Officer (give title below) Other (specify below) Chief Scientific Officer					
(Street) ROCKVILLE, MD 20850				4. If Amendment, Date Original Filed(Month/Day/Year)							n/Day/Year)	_X_ Form	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person				
(City		(State)	(Zip)			Ta	ble I	- Non	-Deriv	ative S	Securities	s Acq	uired, Dis	posed of, or	Beneficially	Owned	
(Instr. 3) Date			2. Transaction Date (Month/Day/Year)	Execu any	A. Deemed execution Date, in the control of the con		(Instr. 8)		(4. Securities Acquir (A) or Disposed of (D) (Instr. 3, 4 and 5)		of	Benefic	ally Owned Following I Transaction(s) and 4)		Ownership Form: Direct (D)	Beneficial Ownership
							С	ode	V	Amount (D) Price		(Instr. 4)					
Common	Common Stock 12/10/2021						P		4,267 (1)		\$ 1.57	85,639	85,639		D		
			Table II - I					quire	contai the fo	ined in rm dis	n this fo splays a of, or Ber	rm a curr	re not rec ently vali	d OMB cor	formation spond unle itrol numbe	ess	2 1474 (9-02)
	ı	I	,	<u> </u>				ts, opt			tible secu				1		
Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Y	Execution Da any	te, if Transaction Code (ear) (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		Ar Un Se	Title and nount of iderlying curities istr. 3 and	Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Owners Form of Derivat Securit Direct or India	Beneficia Ownersh (Instr. 4)		
									Date Exerci	isable	Expiratio Date	n Tit	Amour or Number of				

Reporting Owners

	Relationships							
Reporting Owner Name / Address	Director	10% Owner	Officer	Other				
NEIL GARRY ARTHUR C/O AVALO THERAPEUTICS, INC. 540 GAITHER ROAD, SUITE 400 ROCKVILLE, MD 20850			Chief Scientific Officer					

Signatures

/s/ Michael McInaw, by Power of Attorney	12/14/2021
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) These shares were acquired under the Issuer's 2016 Employee Stock Purchase Plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.